Par Pharmaceutical (PRX) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts PRX Hot Sheet
Price: $49.98 --0%
Financial Fact:
Interest expense: -39.99M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Interest expense: -39.99M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Par Pharmaceutical (NYSE: PRX) reported Q1 EPS of $0.80, $0.08 better than the analyst estimate of $0.72. Revenue for the quarter came in at $271.5 million versus the consensus estimate of $230.84 million.
For earnings history and earnings-related data on Par Pharmaceutical (PRX) click here.
For earnings history and earnings-related data on Par Pharmaceutical (PRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- JPMorgan Upgrades Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) to Neutral
- Coforge Ltd (COFORGE:IN) PT Raised to INR2,460 at UBS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
